IDEXX Laboratories, Inc. $IDXX Shares Purchased by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 23.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 8,564 shares of the company’s stock after acquiring an additional 1,624 shares during the quarter. UniSuper Management Pty Ltd’s holdings in IDEXX Laboratories were worth $5,471,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Bank of New York Mellon Corp increased its position in IDEXX Laboratories by 156.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after purchasing an additional 884,808 shares in the last quarter. Generation Investment Management LLP acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $304,277,000. Norges Bank purchased a new stake in shares of IDEXX Laboratories during the second quarter worth about $221,955,000. Schroder Investment Management Group raised its position in shares of IDEXX Laboratories by 295.1% in the second quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock valued at $169,368,000 after buying an additional 235,863 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. raised its position in shares of IDEXX Laboratories by 50.3% in the second quarter. Montrusco Bolton Investments Inc. now owns 429,409 shares of the company’s stock valued at $224,153,000 after buying an additional 143,641 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.98% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on IDXX shares. Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Barclays assumed coverage on IDEXX Laboratories in a report on Monday, December 8th. They set an “overweight” rating and a $850.00 price objective on the stock. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, January 12th. UBS Group raised their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Finally, Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $763.50.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $693.85 on Monday. The business has a 50-day moving average of $705.83 and a two-hundred day moving average of $656.34. The firm has a market capitalization of $55.40 billion, a PE ratio of 55.02, a P/E/G ratio of 3.71 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The company’s revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.